Bio-Rad Laboratories Inc. (NYSE:BIO) has featured prominently in recent business developments. Its increasing
short interest is being closely scrutinized.
Principal Financial Group Inc. and
ICICI Prudential Asset Management Co Ltd have both strengthened their positions in the company.
VAN ECK ASSOCIATES CORP and
BANK OF NOVA SCOTIA made notable acquisitions. However, the company experienced a fall in stock prices, which depreciated by
54% over the past three years.
Entropy Technologies LP bought 4,200 company shares during this difficult period. Valuation analysis shows that the stock may be overvalued considering the current growth prospects. Several firms, including
Amalgamated Bank and
Kornitzer Capital Management Inc. KS, hold significant shares in Bio-Rad Laboratories. Bio-Rad also outperformed quarterly profit estimates owing to strong sales in its diagnostics unit, rewarding investors with robust growth. Some businesses made new investments, indicating the potential value they see in this company. However, shareholders suffered additional losses with a stock decline of
14%, bringing the three-year losses to
53%.
Bio-Rad Laboratories Stocks News Analytics from Sun, 07 Jun 2015 03:49:27 GMT to Sat, 16 Nov 2024 08:31:03 GMT -
Rating 2
- Innovation 2
- Information 5
- Rumor -6
